Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
- PMID: 32443915
- PMCID: PMC7287876
- DOI: 10.3390/molecules25102380
Ras and Wnt Interaction Contribute in Prostate Cancer Bone Metastasis
Abstract
Prostate cancer (PCa) is one of the most prevalent and malignant cancer types in men, which causes more than three-hundred thousand cancer death each year. At late stage of PCa progression, bone marrow is the most often metastatic site that constitutes almost 70% of metastatic cases of the PCa population. However, the characteristic for the osteo-philic property of PCa is still puzzling. Recent studies reported that the Wnt and Ras signaling pathways are pivotal in bone metastasis and that take parts in different cytological changes, but their crosstalk is not well studied. In this review, we focused on interactions between the Wnt and Ras signaling pathways during each stage of bone metastasis and present the fate of those interactions. This review contributes insights that can guide other researchers by unveiling more details with regard to bone metastasis and might also help in finding potential therapeutic regimens for preventing PCa bone metastasis.
Keywords: Bone metastasis; Cross reaction; Prostate cancer; Ras; Wnt.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
MicroRNA-34a regulates WNT/TCF7 signaling and inhibits bone metastasis in Ras-activated prostate cancer.Oncotarget. 2015 Jan 1;6(1):441-57. doi: 10.18632/oncotarget.2690. Oncotarget. 2015. PMID: 25436980 Free PMC article.
-
MicroRNAs as the critical regulators of bone metastasis during prostate tumor progression.Int J Biol Macromol. 2025 May;309(Pt 2):142912. doi: 10.1016/j.ijbiomac.2025.142912. Epub 2025 Apr 7. Int J Biol Macromol. 2025. PMID: 40203904 Review.
-
FZD8, a target of p53, promotes bone metastasis in prostate cancer by activating canonical Wnt/β-catenin signaling.Cancer Lett. 2017 Aug 28;402:166-176. doi: 10.1016/j.canlet.2017.05.029. Epub 2017 Jun 7. Cancer Lett. 2017. PMID: 28602974
-
MAZ promotes prostate cancer bone metastasis through transcriptionally activating the KRas-dependent RalGEFs pathway.J Exp Clin Cancer Res. 2019 Sep 5;38(1):391. doi: 10.1186/s13046-019-1374-x. J Exp Clin Cancer Res. 2019. PMID: 31488180 Free PMC article.
-
MicroRNAs in the control of metastatic bone disease.Trends Endocrinol Metab. 2014 Jun;25(6):320-7. doi: 10.1016/j.tem.2014.03.014. Epub 2014 May 5. Trends Endocrinol Metab. 2014. PMID: 24811921 Free PMC article. Review.
Cited by
-
Molecular mechanisms and targeted therapy for the metastasis of prostate cancer to the bones (Review).Int J Oncol. 2024 Nov;65(5):104. doi: 10.3892/ijo.2024.5692. Epub 2024 Sep 20. Int J Oncol. 2024. PMID: 39301646 Free PMC article. Review.
-
Wnt/β-catenin signal transduction pathway in prostate cancer and associated drug resistance.Discov Oncol. 2021 Oct 10;12(1):40. doi: 10.1007/s12672-021-00433-6. Discov Oncol. 2021. PMID: 35201496 Free PMC article. Review.
-
Exploration of Extracellular Vesicle miRNAs, Targeted mRNAs and Pathways in Prostate Cancer: Relation to Disease Status and Progression.Cancers (Basel). 2022 Jan 21;14(3):532. doi: 10.3390/cancers14030532. Cancers (Basel). 2022. PMID: 35158801 Free PMC article.
-
WNT ligands in non-small cell lung cancer: from pathogenesis to clinical practice.Discov Oncol. 2023 Jul 24;14(1):136. doi: 10.1007/s12672-023-00739-7. Discov Oncol. 2023. PMID: 37486552 Free PMC article. Review.
-
Identification of novel molecular subtypes and a signature to predict prognosis and therapeutic response based on cuproptosis-related genes in prostate cancer.Front Oncol. 2023 May 2;13:1162653. doi: 10.3389/fonc.2023.1162653. eCollection 2023. Front Oncol. 2023. PMID: 37205181 Free PMC article.
References
-
- Halabi S., Kelly W.K., Ma H., Zhou H., Solomon N.C., Fizazi K., Tangen C.M., Rosenthal M., Petrylak D.P., Hussain M., et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J. Clin. Oncol. 2016;34:1652–1659. doi: 10.1200/JCO.2015.65.7270. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical